Apogee CMO sells shares, exercises options
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises.
Rhea-AI Filing Summary
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises. On May 6, 2026, he completed open-market sales totaling 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share under a pre-arranged Rule 10b5-1 trading plan.
He also exercised 4,125 stock options at an exercise price of $22.86 per share, converting options into common stock. A related option grant covers 175,345 shares that vest in forty-eight equal monthly installments through December 18, 2027, conditioned on his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Dambkowski Carl
Role
Chief Medical Officer
Sold
5,500 shs ($463K)
Approx. gross sale proceeds
$463K
Approx. exercise cost
$94K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,125 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,125 | $22.86 | $94K |
| Sale | Common Stock | 3,700 | $83.92 | $311K |
| Sale | Common Stock | 1,800 | $84.60 | $152K |
Holdings After Transaction:
Stock Option (Right to Buy) — 123,040 contracts (Direct);
Common Stock — 207,023 shares (Direct)
Footnotes (4)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Key Figures
Shares sold (first tranche): 1,800 shares at $84.60
Shares sold (second tranche): 3,700 shares at $83.92
Total shares sold: 5,500 shares
+4 more
7 metrics
Shares sold (first tranche)
1,800 shares at $84.60
Open-market common stock sale on May 6, 2026
Shares sold (second tranche)
3,700 shares at $83.92
Open-market common stock sale on May 6, 2026
Total shares sold
5,500 shares
Net common stock sales per transaction summary
Options exercised
4,125 shares at $22.86
Stock option exercise converting into common stock
Option grant size
175,345 shares
Stock Option (Right to Buy) total underlying shares
Vesting schedule
48 equal monthly installments
Option vests through December 18, 2027
Trading plan adoption date
September 22, 2025
Rule 10b5-1 plan governing May 6, 2026 sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vest in forty-eight equal monthly installments, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... represents the right to purchase 175,345 shares of the Issuer's common stock"
vest in forty-eight equal monthly installments financial
"which will vest in forty-eight equal monthly installments through December 18, 2027"
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
What insider transactions did Apogee Therapeutics (APGE) report for Carl Dambkowski?
Apogee Therapeutics reported that Chief Medical Officer Carl Dambkowski sold 5,500 shares of common stock and exercised 4,125 stock options. These trades occurred on May 6, 2026 and combined open-market sales with a derivative option exercise.
Were Carl Dambkowski’s Apogee Therapeutics (APGE) stock sales pre-planned?
Yes. A footnote states the May 6, 2026 stock sales were executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Such pre-arranged plans automate trading and reduce the significance of timing decisions for interpreting insider sentiment.
What stock options did the Apogee Therapeutics (APGE) CMO exercise?
He exercised 4,125 stock options described as a “Stock Option (Right to Buy)” with an exercise price of $22.86 per share. This converted derivative rights into common stock, reflecting part of a broader equity compensation package disclosed in the filing.
How large is the Apogee Therapeutics (APGE) option grant tied to these exercises?
A footnote explains the option represents the right to purchase 175,345 shares of Apogee common stock. The award vests in forty-eight equal monthly installments through December 18, 2027, contingent on Carl Dambkowski’s continued service with the company.
What is the net effect of the Apogee Therapeutics (APGE) CMO’s recent trades?
The Form 4 summary shows 5,500 shares sold and 4,125 options exercised, resulting in net share sales. While the insider reduced common stock exposure, he also continued using and holding option-based equity compensation, combining liquidity with ongoing alignment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
